THE CURRENT TIME at LC Labs is:
|
|
||||||
|
THE CURRENT TIME at LC Labs is: |
|||||
[Tacrolimus] [Fujimycin] [Prograf]
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
10 mg |
45 |
37 |
25 |
5400 |
| ||
|
25 mg |
89 |
74 |
49 |
10700 |
| ||
|
100 mg |
290 |
241 |
160 |
34800 |
| ||
|
200 mg |
465 |
386 |
256 |
55800 |
| ||
|
500 mg |
695 |
577 |
382 |
83400 |
| ||
| Compare Quality and Prices — LC Labs vs. Other Suppliers | |||
|---|---|---|---|
| US Dollars ($) | European Union Euros (€) | British Pounds (£) | Japanese Yen (¥) |
M.W. 804.03
C44H69NO12
[104987-11-3]
RTECS: KD4200000M.I. 13: 9117
M.I. 14: 9025
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO or ethanol; store solution at or below -20 ºC. Disposal: A
View the MSDS for this product
Ascomycin level is less than 0.5%.
FK-506 is a potent immunosuppressant and in vitro T cell proliferation blocker. It has been shown to disrupt calcineurin (also known as CaN or phosphatase 2B)-mediated signal transduction in T lymphocytes. The compound interacts with its FK506-binding protein-12 (FKBP12). The resulting complex, in turn, interferes with calcineurin substrate interaction. Dumont, F.J. "FK506, an immunosuppressant targeting calcineurin function." Curr. Med. Chem. 7: 731-748 (2000).
FK-506 inhibits FKBP activity resulting in an increase in the release of sarcoplasmic reticulum-derived calcium. FK-506 also appears to inhibit Na(+)-Ca2+ exchange. Prolonged exposure of Xenopus A6 cells to FK-506 significantly inhibits aldosterone-stimulated Na+ transport and Na(+)-K(+)-ATPase activity. Unlike rapamycin, which also binds to FK506-binding protein-12, FKBP12 with or without bound FK506 has no effect on rat brain PKC activity in vitro. McCall, E., et al. "Effects of FK-506 on contraction and Ca2+ transients in rat cardiac myocytes." Circ. Res. 79: 1110-1121 (1996). Rokaw, M.D., et al. "FK-506 and rapamycin but not cyclosporin inhibit aldosterone-stimulated sodium transport in A6 cells." Am. J. Physiol. 271: C194-202 (1996). Rokaw, M.D., et al. "Rapamycin inhibits protein kinase C activity and stimulates Na+ transport in A6 cells." J. Biol. Chem. 271: 32468-32473 (1996).
FK-506 is subject to various Astellas Pharma Inc. patents in the U.S. and certain other countries; not available in some countries; not available to some institutions; not available for some uses.
See also our other standard immunosuppressant products:
Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
© 1990-2008 LC Laboratories All rights reserved.
